Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9B03M026
Published by: Ivey Publishing
Originally published in: 2003
Version: 2009-10-22
Length: 19 pages
Data source: Field research

Abstract

BLES Biochemicals Inc is a research and development company that specializes in natural surfactants. After many years of trying, the president has finally obtained approval for the company''s only product, BLES. The product is used to help premature babies suffering from respiratory distress syndrome - without it, they could die. The company had been allowed to sell the product in advance of receiving the approval but with the news of receiving the go ahead to use and sell the product, the president had to decide his next move. The obvious step would be to pursue international expansion. The worldwide market potential for BLES was incredible. However, there were trade-offs associated with each of the markets under consideration. Moreover, the inherent risks associated with growth gave him cause for concern. He was anxious to develop a growth strategy that explicitly considered the interests of the company, prospective patients, his family, his partners, and his employees. The supplement BLES Biochemicals Inc (B), ''9B03M027'' follows the events six month later.
Location:
Size:
Small
Other setting(s):
2002

About

Abstract

BLES Biochemicals Inc is a research and development company that specializes in natural surfactants. After many years of trying, the president has finally obtained approval for the company''s only product, BLES. The product is used to help premature babies suffering from respiratory distress syndrome - without it, they could die. The company had been allowed to sell the product in advance of receiving the approval but with the news of receiving the go ahead to use and sell the product, the president had to decide his next move. The obvious step would be to pursue international expansion. The worldwide market potential for BLES was incredible. However, there were trade-offs associated with each of the markets under consideration. Moreover, the inherent risks associated with growth gave him cause for concern. He was anxious to develop a growth strategy that explicitly considered the interests of the company, prospective patients, his family, his partners, and his employees. The supplement BLES Biochemicals Inc (B), ''9B03M027'' follows the events six month later.

Settings

Location:
Size:
Small
Other setting(s):
2002

Related